Market Newsdesk

Dynatrace Extends Application Security to .NET

Broad application coverage helps DevSecOps teams mitigate risks and accelerate digital transformation with increased confidence and efficiency

WALTHAM, Mass.–(BUSINESS WIRE)–
Software Intelligence company Dynatrace (NYSE: DT) announced today it has extended its Application Security Module to applications running on .NET, the framework used by more than 5 million developers worldwide. This builds on Dynatrace’s existing support for Java, Node.js, and Kubernetes. As a result, even more organizations can leverage Dynatrace^® Application Security to gain extensive visibility in production and pre-production environments, automatically and continuously prioritize alerts, eliminate false positives, and deliver precise answers about the source, nature, and severity of vulnerabilities.

Rachel Stephens, Senior Industry Analyst at RedMonk, commented, “Organizations operate in a complicated IT landscape. In this polyglot world with multiple hybrid-cloud and multicloud deployment targets, simplicity and security are top concerns. It is difficult for enterprises to keep their entire software stack secure and up to date. Extending application security to include support for the .NET framework is critical for enterprises in their efforts to build secure, innovative applications.”

Sustained interest in .NET reflects organizations’ use of the framework in modern cloud environments, including containers and serverless computing, as well as those that feature extensive open-source components. With this enhancement, Dynatrace provides greater confidence that applications built on the .NET framework, in addition to the libraries they utilize, are free from security exposures.

“Traditional approaches to application security cannot keep up with the complexity of modern cloud environments. Moreover, these approaches are unable to surface accurate and precise vulnerabilities at runtime,” said Steve Tack, SVP of Product Management at Dynatrace. “Dynatrace provides precise risk assessment with code-level detail, prioritization, and remediation for a broad set of application environments, now including .NET. In turn, this enables DevSecOps teams to speed innovation with the confidence that their applications are vulnerability-free.”

These enhancements will be available within the next 30 days. For additional information, please visit the Dynatrace blog.

About Dynatrace

Dynatrace provides software intelligence to simplify cloud complexity and accelerate digital transformation. With automatic and intelligent observability at scale, our all-in-one platform delivers precise answers about the performance and security of applications, the underlying infrastructure, and the experience of all users to enable organizations to innovate faster, collaborate more efficiently, and deliver more value with dramatically less effort. That’s why many of the world’s largest organizations trust Dynatrace®️ to modernize and automate cloud operations, release better software faster, and deliver unrivalled digital experiences.

Curious to see how you can simplify your cloud? Let us show you. Visit our trial page for a free 15-day Dynatrace trial.

To learn more about how Dynatrace can help your business, visit www.dynatrace.com, visit our blog and follow us on Twitter @dynatrace.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005233/en/

Hailey Melamut

March Communications

[email protected]

+1 617.960.9856

Tristan Webb

Spark Communications

[email protected]

+44 207.436.0420

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Networks Security Data Management Technology Software

MEDIA:

Logo

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

GAIN Trial analysis of anti-P. gingivalis antibodies in cerebrospinal fluid supports upstream role of pathogenic bacterium in key Alzheimer’s pathologies

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the presentation of new data demonstrating evidence of P. gingivalis infection of the central nervous system in Alzheimer’s disease at the Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually on Wednesday, August 25, 2021, at 2:10 p.m. ET followed by a live Q&A at 3:40 p.m. ET.

In a featured speaker presentation titled “Use of Novel Biomarkers of P. Gingivalis Infection & Neuroinflammation in the GAIN Trial: An Ongoing Phase 2/3 Clinical Trial Assessing the Activity of Atuzaginstat in Patients with Mild to Moderate Alzheimer’s Disease,” Cortexyme’s Executive Vice President of Research and Development Leslie Holsinger, Ph.D., will present an analysis of anti-P. gingivalis antibodies in cerebrospinal fluid (CSF) with results demonstrating that:

• All patients analyzed at baseline in the GAIN Trial (472 out of 472 baseline CSF samples available) were positive for anti-P. gingivalis antibodies (IgG) in their cerebrospinal fluid;
• Less than 2% of patients analyzed had a leaky blood brain barrier, as defined by an albumin index greater than 9; and
• Anti-P. gingivalis IgG in the CSF was only very weakly correlated to the albumin index (r=0.22), indicating production in the central nervous system in addition to that shown previously in serum.

These data add to the growing body of evidence indicating the presence of a P. gingivalis infection within the central nervous system in patients with Alzheimer’s disease. Cortexyme will also present other novel biomarkers developed to track markers of P. gingivalis and Alzheimer’s disease, in addition to highlighting the upstream role that P. gingivalis plays in key pathologies of Alzheimer’s disease progression. The complete presentation will be available here.

About The GAIN Trial

Cortexyme is pioneering an innovative, upstream, and disease-modifying therapeutic approach to Alzheimer’s disease. The Phase 2/3 GAIN Trial is a pivotal study in 643 patients with mild to moderate Alzheimer’s Disease. Cortexyme’s seminal discovery, along with confirmatory clinical and preclinical studies, demonstrate that the intracellular pathogen, P. gingivalis, is found in the brain of more than 90% of Alzheimer’s patients and that an oral infection with P. gingivalis in animals results in brain infiltration and downstream hallmark Alzheimer’s pathologies, including Aβ42 production, tau hyperphosphorylation, microglial activation, and neurodegeneration. The company’s lead drug candidate, atuzaginstat (COR388), is a first-in-class, orally administered, brain penetrant small molecule targeting P. gingivalis, which is upstream of neuronal death and Alzheimer’s disease pathology. Atuzaginstat blocks gingipains, protease virulence factors secreted byP. gingivalis, which are required for its survival and responsible for its toxicity. The GAIN Trial also includes a REPAIR sub-study of 233 patients targeting P. gingivalis – a keystone bacterium associated with periodontal disease – and measuring the efficacy of atuzaginstat on clinical endpoints of periodontal disease. Cortexyme’s innovative therapeutic approach continues to be supported by research from laboratories around the world published in peer-reviewed scientific journals.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate Alzheimer’s disease with top-line data expected by mid-November 2021, in addition to growing a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson’s disease, periodontitis, and other diseases with high unmet clinical need. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast,” “potential” or other similar words. Examples of forward-looking statements include, among others, statements Cortexyme makes regarding the sufficiency of its cash position to fund its operations; its business plans, strategy, timeline, prospects, and milestone expectations; the timing and success of the company’s clinical trials and related data, including with respect to the GAIN and REPAIR Trials, as well as enabling and human studies of COR588; the potential of atuzaginstat to treat Alzheimer’s disease, periodontal disease, and other potential indications; the potential of COR803 to treat coronavirus infections; the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety and efficacy of the company’s product candidate or library of compounds and statements about its ability to obtain, and the timing relating to, regulatory submissions and approvals with respect to the company’s drug product candidate. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in Cortexyme’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2021, its Quarterly Report on Form 10-Q filed with the SEC on August 6, 2021, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005228/en/

Stacy Roughan

Cortexyme, Inc.

Vice President, Corporate Communications & Investor Relations

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Seniors Biotechnology Pharmaceutical Health Mental Health Consumer Dental Clinical Trials

MEDIA:

Logo

NextGen® Mobile Enables Neighborhood Health to Deliver Care to Nashville’s Homeless Population

Healthcare Providers Extend Their Reach and Improve Outcomes by Using NextGen Healthcare’s Mobile Solution to Access Electronic Health Records in the Field

ATLANTA–(BUSINESS WIRE)–
NextGen® Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced that Neighborhood Health, a federally qualified health center (FQHC) in Tennessee, is using NextGen® Mobile to administer its “street medicine” program to homeless people living in Nashville. The mobile app, which connects to NextGen® Enterprise Electronic Health Record (EHR), provides field doctors with immediate access to a patient’s medical records, prescription lists, appointments and detailed care plans from previous providers. Neighborhood Health currently provides care for more than 600 homeless individuals living on the streets of Nashville.

Homeless encampments and evolving medical technology are strange bedfellows, but since Neighborhood Health has been administering street medicine to Nashville’s homeless community, it has combined the two to completely redefine what is possible for the vulnerable and underserved. Remote EHR access enabled by NextGen Mobile, enables clinicians to provide whole person care to unsheltered communities as opposed to merely treating symptoms.

Neighborhood Health’s street medicine program, powered by NextGen Mobile, has:

• Improved outcomes for patients addicted to opioids by enabling the physician to review medical records and ensure compliance with treatment modalities
• Cautioned a patient receiving a COVID-19 vaccine that his seizure disorder, visible in his health record, was best managed with constant communication with his doctor
• Improved infant mortality statistics for women who did not yet know they were pregnant by referring them to pre-natal care
• Maintained electronic health records for unhoused patients with chronic health conditions (e.g., diabetes, behavioral health disorders) providing informed, real-time visibility into a patient’s complete medical history

“Historically, we would simply have to take the patient’s word on their medical history because we didn’t have access to any sort of medical records,” said Dr. Peter Cathcart for Neighborhood Health. “We obviously couldn’t bring a computer out to the field with us. On NextGen® Mobile, you just tap a few buttons on your cell phone and the records are right there in front of you. It’s a reliable, successful, real-time chart loading for the patients we’re seeing out there.”

“It’s rewarding to witness how Neighborhood Health is using NextGen Mobile to extend the utility of the EHR and meet patients where they are,” said Srinivas Velamoor, chief growth & strategy officer for NextGen Healthcare. “We are pleased to deliver innovative engagement technologies that enable providers to deliver comprehensive care in less traditional venues and address the health needs of the underserved.”

About NextGen® Mobile

NextGen Healthcare’s NextGen® Mobile solution is a user-friendly cloud-based platform that integrates with most EHRs to help providers streamline clinical documentation and improve collaboration. The technology, developed through NextGen’s acquisition of Entrada, Inc. in 2017, alleviates the stress of administrative tasks so providers can practice anytime, anywhere and achieve a healthy work-life balance.

About Neighborhood Health

United Neighborhood Health Services began in 1976 bringing together two volunteer clinics in Cayce Homes and south Nashville. The volunteers wanted to address the lack of accessible and affordable healthcare in south and east Nashville neighborhoods. Nearly 40 years later, they continue to serve the nearby communities. Now known as Neighborhood Health, the organization has grown into a network of 11 centers serving over 31,000 each year, and providing over 90,000 visits each year. With quality comprehensive services and innovative programs, Neighborhood Health has remained passionately committed to its mission to make all services available to everyone without regard to ability to pay.

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of ambulatory-focused technology solutions. We are empowering the transformation of ambulatory care—partnering with medical, behavioral and dental providers in their journey to value-based care to make healthcare better for everyone. We go beyond EHR and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience, and ensure healthy financial outcomes. We believe in better. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005239/en/

Media Contact

Tami Stegmaier

NextGen Healthcare, Inc.

(949) 237-6083

[email protected]

Investor Relations Contact

Matthew Scalo

(415) 370-9202

[email protected]

KEYWORDS: United States North America Tennessee Georgia

INDUSTRY KEYWORDS: Managed Care Software Other Health General Health Mobile/Wireless Pharmaceutical Consumer Technology Medical Devices Fitness & Nutrition Other Consumer Practice Management Health

MEDIA:

Logo

Keysight Technologies to Participate in Upcoming Investor Conferences

SANTA ROSA, Calif.–(BUSINESS WIRE)–
Keysight Technologies, Inc. (NYSE: KEYS), a leading technology company that delivers advanced design and validation solutions to help accelerate innovation to connect and secure the world, announced today that members of its management team will participate in the following virtual investor conferences.

Jefferies Virtual Semiconductor, IT Hardware & Communications Infrastructure Summit

Participants: Jay Alexander, CTO; Mark Wallace, SVP, Global Sales

Wednesday, September 1, 2021

Deutsche Bank 2021 Technology Conference

Presenters: Satish Dhanasekaran, COO; Neil Dougherty, CFO

Thursday, September 9, 2021

10:10 a.m. PT / 1:10 p.m. ET

Citi 2021 Global Technology Virtual Conference

Presenter: Neil Dougherty, CFO

Monday, September 13, 2021

10:00 a.m. PT / 1:00 p.m. ET

A live audio webcast will be available the day of each event and archived at investor.keysight.com, except for the Jefferies Virtual Semiconductor, IT Hardware & Communications Infrastructure Summit.

About Keysight Technologies

Keysight delivers advanced design and validation solutions that help accelerate innovation to connect and secure the world. Keysight’s dedication to speed and precision extends to software-driven insights and analytics that bring tomorrow’s technology products to market faster across the development lifecycle, in design simulation, prototype validation, automated software testing, manufacturing analysis, and network performance optimization and visibility in enterprise, service provider and cloud environments. Our customers span the worldwide communications and industrial ecosystems, aerospace and defense, automotive, energy, semiconductor and general electronics markets. Keysight generated revenues of $4.2B in fiscal year 2020. For more information about Keysight Technologies (NYSE: KEYS), visit us at www.keysight.com.

Additional information about Keysight Technologies is available in the newsroom at www.keysight.com/go/news and on Facebook, LinkedIn, Twitter and YouTube.

Source: IR-KEYS

View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005118/en/

EDITORIAL CONTACT:

Denise Idone, Worldwide

941-888-2388

[email protected]

INVESTOR CONTACT:

Jason Kary

+1 707-577-6916

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Networks Hardware Data Management Technology Software

MEDIA:

Logo

The RMR Group Inc. Declares Special Dividend of $7.00 Per Share

NEWTON, Mass.–(BUSINESS WIRE)–The RMR Group Inc. (Nasdaq: RMR) today announced that it has declared a one-time, special cash dividend on its shares of Class A Common Stock and Class B-1 Common Stock of $7.00 per share to all common stockholders of record as of the close of business on September 6, 2021, payable on or about September 16, 2021. Based on the current number of shares outstanding, the special cash dividend is expected to result in an aggregate distribution of approximately $220 million. This special dividend is in addition to the Company’s regular quarterly cash dividends.

Adam Portnoy, President and Chief Executive Officer, made the following statement:

“Returning excess capital to shareholders in the form of this $7.00 per share special dividend is a key component of RMR’s capital allocation strategy and reflects our strong financial position and confidence in the company’s financial future. Following this distribution, our cash balance remains robust and continues to afford us the flexibility to expand our business both through acquisitions and organic growth.”

About The RMR Group

The RMR Group Inc. (Nasdaq: RMR) is a holding company and substantially all of its business is conducted by its majority owned subsidiary, The RMR Group LLC, or RMR. RMR is a leading U.S. alternative asset management company, unique for its focus on commercial real estate (CRE) and related businesses. RMR’s vertical integration is supported by its more than 600 real estate professionals in over 30 offices nationwide who manage over $32 billion in assets under management and leverage 35 years of institutional experience in buying, selling, financing and operating CRE. RMR benefits from a scalable platform, a deep and experienced management team and a diversity of direct real estate strategies across its clients. RMR is headquartered in Newton, MA and was founded in 1986. For more information, please visit www.rmrgroup.com.

WARNING REGARDING FORWARD LOOKING STATEMENTS

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon RMR’s present beliefs and expectations, but these statements and the implications of these statements are not guaranteed to occur and may not occur for various reasons, some of which are beyond RMR’s control. For example:

• This press release discusses a special dividend to be paid in cash by RMR. A possible implication is that RMR will pay special dividends in the future. The RMR Board of Directors considers many factors when declaring a special dividend, including RMR’s financial position, current and expected earnings, commitments to fund its investments and the availability of cash to fund a special dividend. There can be no assurances that RMR will pay special dividends in the future.
• This press release notes that RMR pays regular quarterly dividend payments. A possible implication is that RMR will continue to pay quarterly dividends. RMR’s dividend rates are set and reset from time to time by RMR’s Board of Directors. The RMR Board of Directors considers many factors when setting dividend rates including RMR’s current and expected earnings, commitments to fund its investments and the availability of cash to fund dividends as compared to alternative uses of such cash. Accordingly, future dividends may be increased or decreased and there is no assurance as to the rate at which future dividends will be paid, and they could decline in amount or be suspended or discontinued.
• This press release states that RMR’s cash balance remains robust and continues to afford RMR the flexibility to expand its business both through acquisitions and organic growth. There can be no assurance that RMR’s expectations or estimates of future developments, including acquisition and other growth opportunities, circumstances or results will materialize.

For these reasons, among others, investors are cautioned not to place undue reliance upon any forward looking statements in this press release. Except as required by law, RMR does not intend to update or change any forward looking statements as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005234/en/

Michael Kodesch

Director, Investor Relations

(617) 796-8230

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo